Iovance Biotherapeutics, Inc

Founded in 1997, ChemoCentryx is a clinical-based pharmaceutical company that discovers and develops orally-administered small molecule therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has developed EnabaLink, which is a drug recovery technology that is designed to accelerate productive drug recovery program. The company also conducts preclinical evaluation of a series of anticancer compounds that target the CXCR7 chemokine receptor. ChemoCentryx evaluates a series of compounds that target the C5a chemo-attractant receptor to treat age-related macular degeneration, rheumatoid arthritis and systemic lupus erythematosus and other disorders. It has entered into a strategic alliance with Glaxo Group, which is an affiliate of GlaxoSmithKline. ChemoCentryx maintains its headquarters in Mountain View, Calif.

Dorian Therapeutics, Inc. is a biotechnology company located in San Carlos, California, focused on advancing scientific research and innovation. The company is committed to addressing significant challenges in the field through its dedicated team of scientists and advisors. With a strong emphasis on collaboration, Dorian Therapeutics engages with various communities to foster knowledge sharing and development. Their mission is to contribute to the scientific landscape by exploring novel therapeutic approaches and solutions. Generated from the website

Acurex Biosciences Corporation, located in San Carlos, CA, is dedicated to advancing drug development for neurodegenerative diseases, particularly Parkinson's disease. The company leverages a proprietary platform based on a breakthrough discovery from Stanford University, focusing on identifying druggable targets that can alter disease progression rather than merely treating symptoms. Acurex's lead drug candidate, CU13001, is an oral, brain-penetrant small molecule designed to utilize their innovative approach to treating Parkinson's disease. This therapy is part of a broader pipeline of early-stage neurology drug candidates aimed at achieving significant biomarker changes in neurological diseases. Generated from the website